Article
HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.
Antiviral research - 1 Jun 2016
Ludmerer Steven W, Hirano Tomona, Black Stuart, Howe Anita Y M, Chang Wei, Takase Akiko, Nakamura Keisuke, Tanaka Yoshiyuki, Kumada Hiromitsu, Hayashi Norio, Nickle David
Abstract excerpt
UNLABELLED: In the phase III registration studies conducted in Japan, Japanese HCV gt1 patients administered vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks achieved SVR24 rates of 83.7-84.5% among treatment-naïve patients, and 92.0-96.2% and 61.9% among breakthrough/relapsers or null-responders to prior interferon based therapy. As evidenced by direct sequencing, patients who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.